AstraZeneca PLC strengthened by Enhertu EU approval. JP Morgan reiterates buy rating on the stock

By Thomas Clarke, Operations & Strategy desk. Reviewed on June 30, 2026 at 2:59 p.m. ET.

AstraZeneca PLC (ISIN US6549022043) is drawing renewed attention after the European Union approved a new use for its cancer medicine Enhertu, expanding the drug across HER2-positive solid tumors as reported in a detailed GlobeNewswire release dated June 29, 2026. At the same time, US-listed AstraZeneca stock trades via its ADRs on OTC markets, providing American investors with direct exposure to the British-Swedish pharma major.

Enhertu secures EU tumour-agnostic approval

According to a GlobeNewswire announcement on June 29, 2026, Enhertu has been approved in the European Union as the first tumour-agnostic HER2-directed therapy and antibody drug conjugate for patients with previously treated HER2-positive metastatic solid tumors. The approval covers a range of solid tumors beyond breast and gastric cancer, reflecting a broader application of HER2-targeted treatment across oncology.

The release highlights that Enhertu’s new EU label opens a larger addressable market, with the drug positioned for use in patients whose tumors express HER2 at significant levels and who have exhausted standard options. The company describes this as the first EU tumour-agnostic approval for a HER2-directed therapy, underscoring the strategic importance of antibody drug conjugates as a growth driver in AstraZeneca’s oncology franchise. For investors, the move reinforces the visibility of future revenues from targeted cancer treatments.

Datroway recommendation and analyst stance

AstraZeneca’s oncology momentum extends beyond Enhertu. A separate GlobeNewswire communication dated June 29, 2026 states that Datroway has received a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) in the EU. The recommendation covers Datroway as first-line treatment for patients with metastatic triple-negative breast cancer who are not candidates for immunotherapy, signaling another potential regulatory milestone for AstraZeneca’s oncology pipeline in Europe.

This combination of a firm EU approval for Enhertu and a CHMP recommendation for Datroway strengthens the company’s position in advanced breast cancer and HER2-positive solid tumors. The regulatory progress comes as analysts continue to assess AstraZeneca’s valuation and growth prospects, with some research houses pointing to the cash flow needed to support continued investment in late-stage trials and commercial launches. The sequence of EU decisions in late June 2026 suggests that oncology will remain the central driver of AstraZeneca’s medium-term earnings story.

On the equity side, a JP Morgan research note reported by MarketScreener on June 30, 2026 indicates that analyst Richard Vosser has maintained a buy rating on AstraZeneca shares. The target price in the note is unchanged at 16,000 GBX, signaling confidence in the company’s long-term growth trajectory despite a recent strong share-price performance and the investment required to sustain its pipeline. The same MarketScreener item mentions that AstraZeneca rose about 0.8 percent among Nordic stocks in North America, a reminder that the company’s equity is actively traded and followed across multiple markets.

Consensus data compiled by Bitget’s analyst forecast overview as of June 30, 2026 show a median 12-month price target for AstraZeneca around 18,451.94 GBX. The same dataset cites a recent closing level of 14,298.00 GBX for AZN stock, implying that the market price currently sits below the Wall Street consensus target range of roughly 15,068.31 GBX to 19,656.69 GBX. For US investors accessing AstraZeneca through its ADRs, these London-based figures provide context for how global analysts see upside and risk in the shares.

Key oncology products and strategy

Beyond Enhertu and Datroway, AstraZeneca’s broader oncology portfolio includes targeted therapies and immuno-oncology agents across breast, lung, hematologic and other cancers. The company has consistently emphasized precision medicine, leveraging biomarkers such as HER2 expression, hormone receptor status and genetic alterations to tailor treatment regimens. This focus aligns with regulatory trends that increasingly favor drugs with strong evidence in well-defined patient subgroups.

In recent years, AstraZeneca has partnered with other biopharma companies, including collaboration with Daiichi Sankyo on antibody drug conjugates such as Enhertu and Datroway. These alliances help share development risk while accelerating access to innovative modalities that combine targeted antibodies with cytotoxic payloads. Investors often view such collaborations as a way to broaden the pipeline without fully bearing the costs and risks of early-stage discovery on every asset.

The EU decisions reported on June 29, 2026 demonstrate how AstraZeneca’s oncology strategy translates into concrete regulatory outcomes. Enhertu’s tumour-agnostic EU approval for HER2-positive solid tumors indicates the regulator’s recognition of robust clinical data across multiple tumor types. Meanwhile, the CHMP’s positive opinion on Datroway for first-line metastatic triple-negative breast cancer suggests that AstraZeneca and its partners are successfully addressing one of the most aggressive and difficult-to-treat breast cancer subtypes.

AstraZeneca PLC stock and latest trading context

According to the Bitget consensus data, AstraZeneca PLC shares on the London Stock Exchange closed at 14,298.00 GBX on the most recent trading day, with a daily change of about -0.14 percent. The same dataset places the median 12-month analyst target around 18,451.94 GBX, indicating that a number of research firms still model upside potential from current levels, driven in part by oncology approvals like Enhertu’s EU decision and Datroway’s expected launch.

This article was generated automatically and technically reviewed before publication. Market prices, analyst data and company information are provided without warranty and may change at short notice. This content is for informational purposes only and is not investment, financial, legal or tax advice. It is not a recommendation to buy or sell any security. Investing in securities involves risk, including the possible loss of principal.